News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CardioDx, Inc. Nixes IPO, Cites Unfavorable Market Conditions



11/15/2013 10:31:01 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CardioDx postpones its initial public offering, citing 'unfavorable market conditions.' California molecular diagnostics company CardioDx spiked its initial public offering, citing "unfavorable market conditions," according to news reports. The 5.8-million-share offering by Palo Alto-based CardioDx was slated to raise $92 million at a share price of $14-$16 apiece. The IPO, originally scheduled for yesterday, would have seen CardioDx shares trade under the "CDX" symbol.

Help employers find you! Check out all the jobs and post your resume.

Read at MassDevice
Read at Silicon Valley
Read at Nasdaq


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES